Archimedes Pharma
READING, England, September 1, 2010 - Archimedes Pharma Ltd., a leading international specialty
pharma company, today announced that the European Commission has granted
marketing authorisation for its lead product, PecFent*, an innovative
fentanyl nasal spray for the treatment of breakthrough cancer pain (BTCP) in
adults who are already receiving maintenance opioid therapy for chronic
cancer pain.
READING, England and BEDMINSTER, New Jersey, August 23, 2010 - Archimedes Pharma, an emerging specialty pharma company focused on
oncology, pain, neurology and critical care sectors, announced today the
location of its new US headquarters in Bedminster, New Jersey.
READING, England, March 2, 2010 - Archimedes Pharma ("Archimedes"), the leading specialty pharma
company, today announced that it has raised GBP65 million (approx US$100
million) in new funding.
